Retinal Drusen Risk and Your Genetics

Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder Reviewed by ExomeDNA Editorial Process Last reviewed: May 26, 2026

Retinal drusen — small extracellular deposits accumulating between the retinal pigment epithelium (RPE) and Bruch's membrane — are the earliest detectable hallmark of age-related macular degeneration (AMD), the leading cause of irreversible central vision loss in adults over 65. CFI, ARMS2, CFH, and C3 are among the highest-confidence genetic signals for retinal drusen risk, with the complement system emerging as the dominant biological pathway linking inherited variation to drusen accumulation and AMD progression.^[1] Below: how complement genetics and retinal biology interact to shape drusen susceptibility, and what population research reveals about the genetic architecture of this vision-threatening trait.

What are retinal drusen?

The retinal pigment epithelium is a monolayer of specialized cells in the outer retina that sits between the photoreceptors (rods and cones) and the choroidal blood supply. RPE cells perform critical metabolic functions: recycling visual pigments, phagocytosing shed photoreceptor outer segment discs, maintaining the outer blood-retinal barrier, and secreting growth factors that support choroidal vasculature. Beneath the RPE lies Bruch's membrane — a pentalaminar basement membrane separating the RPE from the choriocapillaris.

Drusen are deposits that accumulate between the RPE and Bruch's membrane or within Bruch's membrane itself. They contain lipids (including cholesterol esters), complement activation fragments, apolipoprotein E, cellular debris from RPE phagocytosis, and extracellular matrix components. Drusen are classified by size and morphology: small hard drusen (under 63 microns) are common with aging and carry minimal risk; medium-to-large soft drusen (over 63–125 microns) are significantly associated with AMD progression risk; and reticular pseudodrusen carry particularly elevated risk.

The presence of multiple medium-to-large drusen defines intermediate AMD — the stage where complement-mediated damage to the RPE and Bruch's membrane has begun, creating elevated probability of progression toward central vision loss. This stage represents the critical window for monitoring and risk modification.

The genetics of retinal drusen risk

The genetic architecture of retinal drusen is among the most robustly characterized in complex disease genetics. The complement system — particularly the regulatory proteins CFH and CFI alongside the central activation protein C3 — emerges as the dominant genetic risk pathway, with ARMS2 and HTRA1 at the chr10q26 locus as additional high-confidence drusen signals. CFI, ARMS2, C3, CFH, and HTRA1 are among the highest-confidence genetic signals in fine-mapped population data for this trait.^[1]

635,969 diverse U.S. veterans were analyzed across 2,068 health traits in the VA Million Veteran Program (Verma et al. 2024, Science), identifying 13,672 genomic risk loci across diseases and traits including retinal drusen — with complement pathway genes and retinal extracellular matrix loci among the confirmed genetic signals in this ancestry-diverse cohort.^[1]

CFI (complement factor I) is the top-ranked genetic signal for retinal drusen at high confidence. CFI encodes a serine protease that cleaves and inactivates C3b and C4b — the opsonins that amplify complement cascade activation. Without adequate CFI activity, C3b accumulates, complement is over-amplified at the RPE surface, and the resulting chronic sub-RPE inflammatory state drives drusen formation and RPE cell damage. CFH (complement factor H), the primary circulating regulator that blocks C3b from amplifying the alternative complement pathway, is another high-confidence drusen signal. The well-characterized CFH Y402H variant reduces CFH binding to heparan sulfate proteoglycans in RPE tissue, diminishing local complement regulation precisely at the site where drusen accumulate.

CFI and CFH together represent the two primary regulatory checkpoints of the alternative complement pathway at the RPE surface — both appearing as high-confidence genetic signals for retinal drusen, with their combined genetic architecture explaining a substantial fraction of the heritable complement dysregulation that drives drusen formation in susceptible individuals.^[1]

C3 (complement component 3), the central activation node for all three complement pathways, ranks as another high-confidence drusen signal. C3 genetic variants affecting activation kinetics alter complement flux at the RPE-Bruch's membrane interface regardless of which complement pathway is triggered. ARMS2 (age-related maculopathy susceptibility 2) — a small secreted protein of the choroidal extracellular matrix — is one of the most replicated genetic associations in AMD and drusen research; the chr10q26 locus containing both ARMS2 and the adjacent HTRA1 (HtrA serine peptidase 1) is among the most intensively studied in retinal genetics. HTRA1 encodes a serine protease that degrades extracellular matrix proteins in the subretinal space and regulates TGF-β signaling, with the co-expression of ARMS2 and HTRA1 studied as a potential shared functional mechanism at this locus.

CETP (cholesteryl ester transfer protein), which transfers cholesterol esters between HDL and other lipoproteins, appears in drusen genetics reflecting the lipid composition of drusen — drusen deposits contain cholesterol esters and lipid droplets, connecting lipoprotein metabolism to drusen accumulation risk. RDH5, encoding retinol dehydrogenase 5 (which converts 11-cis retinol to 11-cis retinaldehyde in the visual cycle of RPE cells), appears at another drusen locus; variants affecting visual cycle efficiency link RPE metabolic biology to drusen formation susceptibility.

What the research says

Research base: Moderate. The genetic architecture of retinal drusen here is supported by the VA Million Veteran Program genome-wide analysis of 635,969 diverse U.S. veterans across 2,068 traits (Verma et al. 2024, Science), with complement pathway genes, ARMS2/HTRA1, and lipid metabolism loci among the identified signals.^[1] Moderate confidence reflects that the genetic signals for drusen and AMD are among the most replicated in complex disease genetics — with CFH, ARMS2, C3, and CFI confirmed across dozens of independent studies — but this specific profile is grounded in the MVP analysis rather than the larger dedicated AMD GWAS literature. See our methodology page for how we evaluate and apply genetic evidence in your ExomeDNA profile.

How retinal drusen risk affects vision health

Drusen represent the earliest stage of AMD. Most individuals with drusen never progress to advanced AMD, but the presence of multiple medium-to-large soft drusen substantially elevates the probability of progression toward vision-threatening stages over decades. Advanced AMD takes two forms: geographic atrophy (dry AMD), where RPE cells are gradually lost in expanding patches threatening the macula; and neovascular (wet) AMD, where abnormal blood vessel growth under the retina bleeds and rapidly distorts central vision.

Central vision depends on the macula — the 5 mm central region of the retina with the highest density of cone photoreceptors. When drusen accumulate at the macula and AMD advances, the photoreceptors serving central vision are progressively lost. Central vision loss affects reading, driving, and face recognition while peripheral vision typically remains.

A higher genetic risk score reflects greater inherited susceptibility to drusen accumulation and AMD progression — not certainty of vision loss. Protective lifestyle factors, particularly smoking cessation and sun protection, interact with genetic background in determining long-term visual outcomes. Complement pathway genetics shapes the baseline rate of sub-RPE inflammatory activity; environmental exposures determine how much that baseline is amplified over a lifetime.

Working with your retinal drusen result

What research suggests about managing drusen risk

• Smoking cessation: smoking is the strongest modifiable behavioral risk factor for AMD progression — it roughly doubles the risk of advanced AMD and interacts synergistically with high-risk complement and ARMS2 genetic variants.^[1]
• UV eye protection: cumulative UV exposure damages RPE cells and activates complement; quality UV-blocking sunglasses (wraparound, UV400 rated) reduce photooxidative stress at the RPE throughout life.
• Regular retinal monitoring: dilated fundus examinations every 1–2 years provide the imaging needed to detect early drusen, track changes, and identify transitions toward advanced AMD that benefit from treatment.
• AREDS2 supplementation for intermediate AMD: for individuals with multiple medium-to-large drusen, the AREDS2 formula (vitamins C, E, zinc, copper, lutein, zeaxanthin) has clinical evidence for reducing the risk of progression to advanced AMD — this is a specific intermediate-stage recommendation for clinical discussion.
• Mediterranean dietary pattern: rich in oily fish, leafy greens, and antioxidants, this dietary approach associates with reduced AMD risk in observational studies; omega-3 fatty acids may support RPE membrane health.
• Home Amsler grid monitoring: for individuals with known drusen, regular home testing can detect early signs of neovascular AMD (central distortion) between ophthalmology visits, enabling earlier treatment.

Related traits and genes

Retinal drusen risk connects directly to Age-Related Macular Degeneration Risk, for which drusen represent the defining intermediate-stage biomarker — the ARMS2, CFH, C3, and CFI genetic signals for drusen are shared with AMD genetics. Complement System Activity reflects the underlying immune regulation pathway where CFH and CFI variants determining drusen risk also shape systemic complement biology. HDL Cholesterol Levels connects through the CETP locus — lipid metabolism and HDL overlap between cardiovascular and retinal health genetics.

For vision health, Myopia Risk and Glaucoma Risk are distinct retinal and optic nerve conditions sharing the anatomical space but with different genetic architectures. Macular Thickness reflects RPE health and retinal structure at the region most affected by drusen accumulation over time.

Frequently asked questions

What are retinal drusen and why do they matter?

Drusen are deposits accumulating beneath the RPE between the retina and its blood supply — composed of lipids, complement fragments, and cellular debris. They represent the earliest AMD stage. Small hard drusen (under 63 microns) are common with aging and benign. Medium-to-large soft drusen mark a stage where RPE health is compromised and the probability of advancing toward central vision loss increases substantially over time. The genetic variants in this trait influence how rapidly and extensively drusen accumulate in susceptible individuals as they age.

Why is the complement system so central to drusen genetics?

The RPE-Bruch's membrane interface is among the highest metabolic-demand tissue junctions in the body, continuously generating oxidative debris that the complement system helps clear. When complement regulatory proteins CFH and CFI function well, complement activation is tightly limited to debris only, protecting RPE cells from collateral damage. Variants reducing CFH or CFI activity allow complement overactivation — the resulting chronic sub-RPE inflammatory state deposits complement fragments in drusen and directly damages RPE cells. Complement genetics reflects how tightly controlled inflammation is essential to retinal maintenance across a lifetime.

What is ARMS2 and why is it one of the strongest drusen genetic signals?

ARMS2 encodes a small secreted protein that localizes to the choroidal extracellular matrix beneath the RPE. ARMS2 variants — particularly at the chr10q26 locus that also contains HTRA1 — are among the most replicated genetic associations in all AMD and drusen research. The chr10q26 locus is the second-strongest AMD genetic signal after the CFH region, and ARMS2 and HTRA1 are studied together as a potentially shared functional mechanism involving extracellular matrix degradation and protease activity at the Bruch's membrane interface where drusen accumulate.

Does the cholesterol gene CETP really affect eye health?

Yes, through the lipid composition of drusen. Drusen deposits contain cholesterol esters, lipid droplets, and apolipoprotein-containing particles — reflecting a lipid metabolism dimension to AMD recognized since the 1990s. CETP, which transfers cholesterol esters between HDL and other lipoproteins, affects lipid content and handling in RPE cells and the subretinal space. Variants at the CETP locus in drusen GWAS reflect biological overlap between lipoprotein metabolism and the lipid-rich extracellular deposits at the RPE — connecting retinal health genetics to the same lipid biology relevant to cardiovascular disease.

Can drusen be reversed or prevented?

Drusen cannot currently be reversed once established — no proven treatment eliminates existing deposits. Prevention focuses on modifying factors that drive accumulation: smoking cessation, UV protection, and managing the complement activation that fuels formation. For individuals with intermediate AMD (multiple medium-to-large drusen), AREDS2 supplementation has clinical evidence for slowing progression toward advanced AMD stages. Genetic variants in this trait indicate inherited susceptibility — lifestyle modifications and monitoring can meaningfully alter the progression trajectory over decades.

References

1. Verma A, et al. (2024). Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. Science. PMID: 39024449. DOI: 10.1126/science.adj1182.

Data sources:

• GWAS Catalog (NHGRI-EBI, accessed 2026-05-26)
• Open Targets Platform (CC0 1.0, accessed 2026-05-26)
• ClinVar (NCBI, accessed 2026-05-26) — entries at ≥2-star review status
• ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-26)

This page is published by the ExomeDNA Research Team. Last reviewed: 2026-05-26.